Why should addiction treatment be restricted to late-stage addicts and expensive specialists?  Dr. Joshua D. Lee provides an alternate vision.  An associate professor at the NYU Grossman School of Medicine and director of the NYU Fellowship in Addiction Medicine, Dr. Lee is a clinician-researcher focused on investigating addiction pharmacotherapies in primary care and criminal justice system-involved populations. He has conducted multiple NIH clinical trials examining the use of naltrexone and buprenorphine opioid and alcohol treatments in criminal justice system-involved adults, at community re-entry, and within primary care settings.